<DOC>
	<DOC>NCT01432262</DOC>
	<brief_summary>The purpose of this study will be to assess the safety, tolerability, and immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) when given to healthy adults older than 50 years of age who haven't received 23-valent pneumococcal polysaccharide vaccine in Mexico.</brief_summary>
	<brief_title>13-valent Pneumococcal Conjugate Vaccine Study in Adults =&gt; 50 Years of Age in Mexico</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male or female older than 50 years of age Eligibility must be determined by medical history, physical exam and clinical judgment Able to complete an electronic diary Available for duration of study Negative pregnancy test for subjects in group 2 age 50 to 64 years Practice abstinence or use reliable birth control if age is 50 to 64 years History of allergic reaction to any vaccine Previous vaccination with licensed or experimental pneumococcal vaccine S. pneumonia infection within past 5 years before investigational product administration Known or suspected immunodeficiency or received treatment including cytotoxic agents or systemic corticosteroids, serious chronic disorder such as malignancy cancer Receipt of plasma products or immunoglobulins within 60 days Bleeding conditions or diathesis Receipt of investigational product within 28 days before study entry Other severe acute or chronic medical or psychiatric condition</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>prevention of pneumococcal diseases</keyword>
</DOC>